Which has better valuation & earnings, DXCM or HQY?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.82B 5.82 $836.30M $2.34 31.04 HealthEquity $1.31B 5.45 $215.20M $2.67 32.09

Is DXCM or HQY more profitable?

DexCom has a net margin of 19.31% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 33.33% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% HealthEquity 17.25% 14.75% 9.22%

Does the media refer more to DXCM or HQY?

In the previous week, HealthEquity had 2 more articles in the media than DexCom. MarketBeat recorded 24 mentions for HealthEquity and 22 mentions for DexCom. DexCom's average media sentiment score of 1.25 beat HealthEquity's score of 0.59 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.66 $247.10M $4.30 33.31 DexCom $4.82B 5.82 $836.30M $2.34 31.04

Is PODD or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% DexCom 19.31% 33.33% 13.19%

Does the media refer more to PODD or DXCM?

In the previous week, DexCom had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for DexCom and 14 mentions for Insulet. DexCom's average media sentiment score of 1.25 beat Insulet's score of 0.19 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DXCM or ABT?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.82B 5.82 $836.30M $2.34 31.04 Abbott Laboratories $45.13B 3.37 $6.52B $3.57 24.48

Is DXCM or ABT more profitable?

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Abbott Laboratories 13.90% 17.62% 10.01%

Does the media prefer DXCM or ABT?

In the previous week, Abbott Laboratories had 12 more articles in the media than DexCom. MarketBeat recorded 34 mentions for Abbott Laboratories and 22 mentions for DexCom. DexCom's average media sentiment score of 1.25 beat Abbott Laboratories' score of 0.91 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 26 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor AMN or DXCM?

In the previous week, DexCom had 8 more articles in the media than AMN Healthcare Services. MarketBeat recorded 22 mentions for DexCom and 14 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 1.25 beat AMN Healthcare Services' score of 0.17 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DXCM or ITGR?

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.82B 5.82 $836.30M $2.34 31.04 Integer $1.85B 1.65 $102.81M $4.01 22.44

Is DXCM or ITGR more profitable?

DexCom has a net margin of 19.31% compared to Integer's net margin of 7.64%. DexCom's return on equity of 33.33% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Integer 7.64% 12.83% 6.51%

Does the media prefer DXCM or ITGR?

In the previous week, DexCom had 20 more articles in the media than Integer. MarketBeat recorded 22 mentions for DexCom and 2 mentions for Integer. DexCom's average media sentiment score of 1.25 beat Integer's score of -0.27 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DexCom (DXCM) Competitors

$72.48 -0.97 (-1.32%)

As of 11:15 AM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? MarketBeat compares DexCom with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). These companies are all part of the "medical" sector.

How does DexCom compare to HealthEquity?

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

DexCom presently has a consensus price target of $82.42, indicating a potential upside of 13.47%. HealthEquity has a consensus price target of $111.53, indicating a potential upside of 30.16%. Given HealthEquity's higher possible upside, analysts plainly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, HealthEquity had 2 more articles in the media than DexCom. MarketBeat recorded 24 mentions for HealthEquity and 22 mentions for DexCom. DexCom's average media sentiment score of 1.25 beat HealthEquity's score of 0.59 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.82B	5.82	$836.30M	$2.34	31.04
HealthEquity	$1.31B	5.45	$215.20M	$2.67	32.09

DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, HealthEquity has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

DexCom has a net margin of 19.31% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 33.33% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
HealthEquity	17.25%	14.75%	9.22%

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.6% of HealthEquity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

DexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.66	$247.10M	$4.30	33.31
DexCom	$4.82B	5.82	$836.30M	$2.34	31.04

Insulet has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, DexCom had 8 more articles in the media than Insulet. MarketBeat recorded 22 mentions for DexCom and 14 mentions for Insulet. DexCom's average media sentiment score of 1.25 beat Insulet's score of 0.19 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet currently has a consensus target price of $252.04, indicating a potential upside of 75.98%. DexCom has a consensus target price of $82.42, indicating a potential upside of 13.47%. Given Insulet's higher possible upside, research analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	19.31%	33.33%	13.19%

Summary

DexCom beats Insulet on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Abbott Laboratories had 12 more articles in the media than DexCom. MarketBeat recorded 34 mentions for Abbott Laboratories and 22 mentions for DexCom. DexCom's average media sentiment score of 1.25 beat Abbott Laboratories' score of 0.91 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	26 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.82B	5.82	$836.30M	$2.34	31.04
Abbott Laboratories	$45.13B	3.37	$6.52B	$3.57	24.48

DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Abbott Laboratories	13.90%	17.62%	10.01%

DexCom presently has a consensus target price of $82.42, indicating a potential upside of 13.47%. Abbott Laboratories has a consensus target price of $119.09, indicating a potential upside of 36.27%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

97.8% of DexCom shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

DexCom beats Abbott Laboratories on 10 of the 16 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$3.42B	0.34	-$95.70M	-$0.87	N/A
DexCom	$4.82B	5.82	$836.30M	$2.34	31.04

In the previous week, DexCom had 8 more articles in the media than AMN Healthcare Services. MarketBeat recorded 22 mentions for DexCom and 14 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 1.25 beat AMN Healthcare Services' score of 0.17 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AMN Healthcare Services currently has a consensus price target of $25.29, indicating a potential downside of 14.63%. DexCom has a consensus price target of $82.42, indicating a potential upside of 13.47%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

AMN Healthcare Services has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

DexCom has a net margin of 19.31% compared to AMN Healthcare Services' net margin of -0.95%. DexCom's return on equity of 33.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
DexCom	19.31%	33.33%	13.19%

Summary

DexCom beats AMN Healthcare Services on 15 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

DexCom (NASDAQ:DXCM) and Integer (NYSE:ITGR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.1% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DexCom currently has a consensus target price of $82.42, indicating a potential upside of 13.47%. Integer has a consensus target price of $98.71, indicating a potential upside of 9.68%. Given DexCom's stronger consensus rating and higher probable upside, equities research analysts clearly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.82B	5.82	$836.30M	$2.34	31.04
Integer	$1.85B	1.65	$102.81M	$4.01	22.44

DexCom has a net margin of 19.31% compared to Integer's net margin of 7.64%. DexCom's return on equity of 33.33% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Integer	7.64%	12.83%	6.51%

DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Integer has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, DexCom had 20 more articles in the media than Integer. MarketBeat recorded 22 mentions for DexCom and 2 mentions for Integer. DexCom's average media sentiment score of 1.25 beat Integer's score of -0.27 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DexCom beats Integer on 14 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.03B	$6.99B	$6.24B	$12.48B
Dividend Yield	N/A	1.21%	2.69%	5.30%
P/E Ratio	31.04	45.45	21.09	24.35
Price / Sales	5.82	85.63	561.45	126.00
Price / Cash	27.04	24.40	42.31	57.88
Price / Book	10.32	7.27	9.95	6.72
Net Income	$836.30M	$159.22M	$3.56B	$337.08M
7 Day Performance	3.37%	1.93%	-0.07%	1.63%
1 Month Performance	18.39%	5.81%	5.08%	6.29%
1 Year Performance	-16.32%	3.66%	28.39%	35.50%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	4.4742 of 5 stars	$72.48 -1.3%	$82.42 +13.7%	-14.1%	$27.97B	$4.82B	30.97	11,000	Positive News Analyst Forecast
HQY HealthEquity	4.4121 of 5 stars	$90.64 +3.0%	$111.53 +23.1%	-14.1%	$7.58B	$1.31B	33.95	2,814	Earnings Report Analyst Forecast Insider Trade
PODD Insulet	4.1373 of 5 stars	$148.13 +2.2%	$252.04 +70.2%	-56.2%	$10.26B	$2.71B	34.45	5,400	Analyst Forecast
ABT Abbott Laboratories	4.9567 of 5 stars	$87.70 +2.5%	$119.09 +35.8%	-34.8%	$152.75B	$44.33B	24.57	115,000
AMN AMN Healthcare Services	1.6263 of 5 stars	$29.47 +1.7%	$25.29 -14.2%	+48.2%	$1.14B	$2.73B	N/A	2,664	Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors